Annual Bleeding Rates: Pitfalls of Clinical Trial Outcomes in Hemophilia Patients

Emerging treatment options for hemophilia, including gene therapy, modified factor products, antibody‐based products, and other nonreplacement therapies, are in development or on their way to marketing authorization. For proof of efficacy, annual bleeding rates (ABRs) have become an increasingly imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Keipert, Christine, Müller‐Olling, Mirco, Gauly, Franca, Arras‐Reiter, Cornelia, Hilger, Anneliese
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719362/
https://www.ncbi.nlm.nih.gov/pubmed/32472976
http://dx.doi.org/10.1111/cts.12794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719362/
https://www.ncbi.nlm.nih.gov/pubmed/32472976
http://dx.doi.org/10.1111/cts.12794

Ejemplares similares